Ovarian Cancer Clinical Trials in Oklahoma City, Oklahoma

13 studies are recruiting for ovarian cancer in Oklahoma City, Oklahoma right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of Oklahoma, Oklahoma City, Oklahoma

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

   This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   OU Health, Stephenson Cancer Center, Oklahoma City, Oklahoma

   Locations

   4 in total

   Run by

   Imunon

   See if you can join NCT05739981 on ClinicalTrials.gov

3. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

   The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjuga…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma

   Locations

   29 in total

   Run by

   Tubulis GmbH

   See if you can join NCT06303505 on ClinicalTrials.gov

4. Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

   The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

   Stage

   Phase 1

   Ages

   15 and older

   Site

   OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma

   Locations

   22 in total

   Run by

   Xencor, Inc.

   See if you can join NCT06276491 on ClinicalTrials.gov

5. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

   This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Normunity Investigational Site, Oklahoma City, Oklahoma

   Locations

   18 in total

   Run by

   Normunity AccelCo, Inc.

   See if you can join NCT07182149 on ClinicalTrials.gov

6. Clinical Pre-screening Protocol for Ovarian Cancer

   The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Th…

   Stage

   Not phased

   Ages

   18 and older

   Site

   OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma

   Locations

   9 in total

   Run by

   Allarity Therapeutics

   See if you can join NCT03877796 on ClinicalTrials.gov

7. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

   This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stephenson Cancer Center, Oklahoma City, Oklahoma

   Locations

   82 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT04657068 on ClinicalTrials.gov

8. Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

   The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα rec…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Oklahoma, Oklahoma City, Oklahoma

   Locations

   9 in total

   Run by

   University of Alabama at Birmingham

   See if you can join NCT04606914 on ClinicalTrials.gov

9. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

   A Study of Emi-Le in Participants with Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stephenson Cancer Center Oklahoma University Health, Oklahoma City, Oklahoma

   Locations

   26 in total

   Run by

   Day One Biopharmaceuticals, Inc.

   See if you can join NCT05377996 on ClinicalTrials.gov

10. Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

    The goal of this clinical research study is to find out if combining a standard blood test (CA-125) that checks for ovarian cancer with other blood tests that check for related tumor markers may be helpful in the early detection of ovarian cancer in women who are at low risk. Tumor markers are subs…

    Stage

    Not phased

    Ages

    50 to 74

    Site

    University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

    Locations

    12 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT00539162 on ClinicalTrials.gov

11. A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

    The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, wh…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma

    Locations

    28 in total

    Run by

    Compugen Ltd

    See if you can join NCT06888921 on ClinicalTrials.gov

12. A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

    This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Stephenson Cancer Center, Oklahoma City, Oklahoma

    Locations

    15 in total

    Run by

    OnCusp Therapeutics, Inc.

    See if you can join NCT06234423 on ClinicalTrials.gov

13. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

    A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dren Investigational Site, Oklahoma City, Oklahoma

    Locations

    10 in total

    Run by

    Dren Bio

    See if you can join NCT06999187 on ClinicalTrials.gov